Latanoprost Stulln

Latanoprost, the active ingredient in Latanoprost Stulln, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension. It is indicated for patients with elevated intra‑ocular pressure to prevent optic nerve damage.

GNH USA supplies Latanoprost Stulln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant shipments to global markets.

Latanoprost is used to reduce intra‑ocular pressure in several glaucoma‑related conditions.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: reduces eye pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: decreases intra‑ocular pressure to protect visual field.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: transient burning or stinging sensation. - Blurred vision: temporary visual disturbance after instillation. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual increase in pigmentation. - Eye discomfort: sensation of foreign body.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract requiring medical attention. - Corneal edema: swelling of the cornea that may affect vision. - Persistent eye pain: ongoing discomfort beyond the initial period. - Vision loss: rare but serious deterioration of visual acuity. - Iris depigmentation: loss of iris color, potentially permanent.

Before initiating therapy with Latanoprost, consider the following safety measures.

- Monitor intra‑ocular pressure: regular eye examinations are required to assess efficacy. - Avoid use in active ocular infection: may exacerbate the condition. - Do not combine with other prostaglandin analogs: risk of additive pressure‑lowering effect. - Caution in patients with a history of uveitis: may trigger inflammation. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing intra‑ocular pressure control.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect may lead to hypotony. - Miotic agents: may counteract the pressure‑lowering action of Latanoprost.

Moderate Interactions (Monitor Closely): - Topical beta‑blocker eye drops: monitor for excessive pressure reduction. - Corticosteroid eye drops: may diminish response; regular IOP checks advised. - Herbal supplements affecting prostaglandin pathways: observe for changes in IOP control.